Selecting an AI vendor is one of the highest-stakes decisions a pharma company makes when adopting these systems, since switching costs are real once a workflow is built around a specific platform. This FAQ answers the questions procurement, IT, and business teams should work through before signing with an AI vendor.
1. What criteria matter most when selecting an AI vendor for pharma?
The criteria that matter most are proven experience in regulated industries, demonstrated multilingual accuracy for Indian languages, strong data security practices, and the ability to integrate with the company's existing CRM, ERP, or quality systems. A vendor may have an impressive general AI product, but if it has never worked with a regulated healthcare or pharma client, it may lack the compliance and audit-trail features pharma workflows require. Companies should weight these criteria according to their specific use case — data security and compliance matter most for anything touching patient or pharmacovigilance data, while integration depth matters most for CRM-linked field force tools.
2. Should a pharma company choose a specialized pharma AI vendor or a general-purpose AI platform?
A specialized vendor with pharma or healthcare experience is generally a safer choice for use cases involving patient data, doctor interactions, or regulatory documentation, because they typically already understand compliance requirements and common workflow patterns specific to the industry. General-purpose AI platforms can work well for less regulated internal use cases, such as basic document summarization, but pharma companies often find themselves doing significant additional configuration work to bring a general platform up to the compliance standard a specialized vendor would offer out of the box. It is reasonable to use different vendors for different use cases rather than assuming one platform must handle everything.
3. What questions should a pharma company ask an AI vendor during evaluation?
Key questions include how the vendor handles data security and residency, what industries and regulated clients they have prior experience with, how their system supports Indian regional languages, what the implementation timeline typically looks like, and how pricing scales with usage. It is also worth asking directly for a reference client in a similar regulated industry, since a vendor's marketing claims about compliance readiness should be verifiable through an existing customer's actual experience. Vendors who are evasive about specific security or compliance questions, or unable to provide any reference in a regulated sector, are a meaningful red flag.
4. How important is multilingual capability when choosing an AI vendor for Indian pharma?
Multilingual capability is critical for any pharma AI use case touching patients, pharmacies, or field staff outside major metro areas, since a large share of India's population is more comfortable communicating in a regional language than in English or even standard Hindi. A vendor that only supports English and Hindi will significantly limit the reach of a patient adherence program or MR support tool intended for pan-India deployment. Pharma companies should specifically test a shortlisted vendor's language performance against real regional dialects relevant to their patient or doctor base, not just standard textbook language samples provided in a demo.
5. What red flags should pharma companies watch for when evaluating AI vendors?
Red flags include vague answers about data security and compliance, no prior experience with regulated industry clients, unwillingness to provide a reference customer, and pricing structures that lack transparency about what happens as usage scales. Vendors who oversell what their AI can do — claiming it can make independent clinical or regulatory decisions, for instance — should also raise concern, since this suggests either a misunderstanding of pharma compliance requirements or an intent to overstate capability during the sales process. A vendor's willingness to be specific and honest about the limits of their system is often a better trust signal than an impressively broad feature list.
6. Does it matter whether an AI vendor has experience specifically in Indian pharma, versus global pharma?
It matters meaningfully, because Indian pharma operates under a distinct regulatory framework through CDSCO, has pricing controls through NPPA that differ from global markets, and serves a patient base with linguistic and access patterns very different from Western markets. A vendor with only global pharma experience may not be familiar with generic substitution rules, Jan Aushadhi Kendra dynamics, or the linguistic diversity relevant to a pan-India rollout. This does not rule out global vendors entirely, but pharma companies should probe specifically for India-relevant experience and ask how the vendor has adapted its platform for the Indian regulatory and linguistic context.
7. How should a pharma company evaluate an AI vendor's integration capabilities?
A pharma company should ask for specifics on which CRM, ERP, or quality management systems the vendor has previously integrated with, how long typical integrations take, and whether the vendor uses standard APIs or requires custom development for each client. Integration complexity is one of the most common sources of implementation delay, so vendors who can point to prior integrations with systems similar to what the company already runs are a much lower-risk choice than vendors proposing to build a custom integration from scratch. It is also worth clarifying who owns ongoing maintenance of the integration once it is live.
8. Should pharma companies run a proof of concept before committing to an AI vendor contract?
Yes, running a scoped proof of concept or pilot before a full commercial commitment is strongly advisable, since it allows the company to validate the vendor's claims about accuracy, language support, and integration ease against its own real data and workflows rather than a generic vendor demo. A proof of concept should have clearly defined success criteria agreed upon before it starts, so both the pharma company and the vendor have a shared, objective basis for deciding whether to proceed to full deployment. Vendors confident in their platform are typically willing to support a reasonably scoped proof of concept without requiring a large upfront commitment.
9. How should pharma companies think about vendor lock-in when choosing an AI platform?
Pharma companies should ask vendors directly about data portability — how easily historical interaction data, configurations, and trained models can be exported or migrated if the company decides to switch vendors later. Some degree of lock-in is inevitable with any platform investment, but a vendor that makes data export difficult or charges punitive fees for migration is a warning sign worth factoring into the decision. It is reasonable to negotiate data portability terms explicitly in the contract rather than assuming they will be straightforward to arrange after the fact.
10. What is a reasonable timeline for a pharma company to complete vendor evaluation and selection?
A reasonable vendor evaluation timeline is typically six to ten weeks, covering initial vendor research, detailed evaluation against defined criteria, a short proof of concept with the top one or two candidates, and final contract negotiation. Rushing this process to a few weeks often means skipping meaningful due diligence on compliance and security, while dragging it out over many months risks losing organizational momentum and stakeholder interest in the project. Setting a clear evaluation timeline with defined milestones at the outset helps keep the process disciplined without sacrificing the diligence a regulated industry decision requires.
Related Reading
Related reading
Talk to YuVerse
See how YuVerse stacks up against your vendor evaluation criteria: talk to us.